Treatment of CD4 T-cell mediated conditions
OwnerAndrew D. Weinberg, Arthur A. Vandenbarkinventors
Life of this patent
Estimating the term…
Abstract
A method for the selective depletion of activated CD4.sup.+ T-cells in vivo by using immunotoxins comprising the OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4.sup.+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis. This type of therapy is also beneficial for eradicating CD4.sup.+ T-cell lymphomas and alloreactive CD4.sup.+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.
Claims23
A method of treating a human patient suffering from a condition mediated by activated CD4.sup.+ T-cells expressing an OX-40 antigen, comprising administering to the patient a therapeutically effective amount of a cytotoxic agent conjugated to an antibody that is capable of binding specifically to a human OX-40 antigen having the amino acid sequence set forth in Seq. I.D. No. 1.
A method of treating a human patient suffering from a condition mediated by activated CD4.sup.+ T-cells expressing an OX-40 antigen comprising administering to the patient a cytotoxic conjugate comprising a Fab, F(ab').sub.2 or Fv fragment of a monoclonal antibody conjugated with a cytotoxic agent and wherein said fragment is capable of binding specifically to an OX-40 antigen having the amino acid sequence set forth in Seq. I.D. No. 1.
A method for reducing a population of CD4+ T-cells that express an OX-40 antigen in a human comprising administering an effective amount of an antibody-cytotoxin conjugate wherein the antibody is capable of binding specifically to a human OX-40 peptide having the amino acid sequence shown in Seq. I.D. No. 1.
A method of reducing autoimmune inflammation in a human patient suffering from multiple sclerosis, comprising the steps of:
- diagnosing an acute autoimmune inflammation in the patient;
- administering to the patient a therapeutically effective amount of an immunotoxin wherein said immunotoxin binds specifically to a human OX-40 cell surface antigen having the amino acid sequence set forth in Seq. I.D. No. 1.
A method for reducing a population of antigen activated CD4+ T-cells that express an Ox-40 antigen in a human subject comprising administering to the subject a therapeutically effective amount of an antibody capable of binding specifically to a human peptide having an amino acid sequence set forth in Seq. I.D. No. 1.
A method for depleting from the body of a human subject CD4+ T-cells that express an Ox-40 antigen, the method comprising administering a therapeutically effective amount of a specific binding agent to the subject wherein the specific binding agent is capable of binding specifically to a human Ox-40 antigen having the amino acid sequence set forth in Seq. I.D. No. 1 and wherein the specific binding agent is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, and fragments of monoclonal antibodies.
A method of treating a human patient suffering from a condition mediated by activated CD4.sup.+ T-cells expressing an OX-40 antigen, the method comprising administering to the patient a therapeutically effective amount of a specific binding agent selected from the group consisting of antibodies and fragments thereof that specifically bind a human Ox-40 antigen having the sequence set forth in Seq. I.D No. 1.
Dependencies are inferred from the claim text.